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Background. Due to underrepresentation of patients with chronic kidney disease (CKD) in large Implantable-Cardioverter
Deﬁbrillator (ICD) clinical trials, the impact of ICD remains uncertain in this population. Methods. Consecutive patients who
received ICD at Creighton university medical center between years 2000–2004 were included in a retrospective cohort after
excluding those on maintenance dialysis. Based on baseline Glomerular ﬁltration rate (GFR), patients were classiﬁed as severe
CKD: GFR < 30mL/min; moderate CKD: GFR: 30–59mL/min; and mild or no CKD: GFR ≥ 60mL/min. The impact of GFR on
appropriate shocks and survival was assessed using Kaplan-Meier method and Generalized Linear Models (GLM) with log-link
function. Results.There were 509 patients witha mean follow-upof3.0 +1.3 years.Mortalityriskwasinverselyproportionalto the
estimated GFR: 2 fold higher risk with GFR between 30–59mL/min and 5 fold higher risk with GFR < 30mL/min. One hundred
and seventy-seven patients received appropriate shock(s); appropriate shock-free survival was lower in patients with severe CKD
(GFR < 30) compared to mild or no CKD group (2.8 versus 4.2yrs). Conclusion. Even moderate renal dysfunction increases all
cause mortality in CKD patients with ICD. Severe but not moderate CKD is an independent predictor for time to ﬁrst appropriate
shock.
1.Introduction
Chronic kidney disease (CKD) is present among 17% of the
US adult population and is a strong and independent
predictor of cardiovascular events, ventricular arrhythmias,
and sudden death [1, 2]. This is true even in early stages
of CKD and in patients who are not dialysis dependant [2].
Sudden cardiac death (SCD) accounts for up to 25% of the
all cause mortality and 60% of cardiac deaths in dialysis-
dependant patients [1, 3]. Multiple trials have demonstrated
the survival beneﬁts of Implantable-Cardioverter Deﬁbrilla-
tors (ICD) in the primary and secondary prevention of SCD
in patients fulﬁlling broad inclusion criteria [4, 5]. However,
due to underrepresentation of patients with CKD in these
large ICD clinical trials, outcomes remain uncertain in this
population. Prior observational studies have shown that
despite the high risk of SCD, patients with advanced CKD
do not derive signiﬁcant beneﬁt from ICD implantation and
continue to have substantial mortality [6–10]. However, a
majority of the above trials included patients with end-stage
renal failure on maintenance dialysis. The impact of less
advanced CKD (non dialysis dependant) in patients with
ICDremainsunclear.Similarly,priorstudieshaveshownthat
need for dialysis is a predictor of appropriate ICD therapy;
h o w e v e r ,t h ei m p a c to fm o d e r a t eC K Do nt h ef r e q u e n c ya n d
time to appropriate shock is less explored.2 Cardiology Research and Practice
2.Methods
This was a retrospective cohort study and included consecu-
tive patients who underwent ICD implantation at Creighton
University Medical Center from January 2000 to December
2004. Patients with end-stage renal failure on maintenance
dialysis at the time of implantation were excluded. Baseline
demographics, clinical, echocardiographic, laboratory, and
treatment data including indication for ICD implanta-
tion (primary or secondary), New York Heart Association
(NYHA)class of heart failure, Left Ventricular Ejection Frac-
tion (LVEF), QRS duration, and medications were noted.
All patients undergoing device implantation in our institute
get a basic metabolic panel and complete blood count as a
part of preoperative work up within a week before surgery.
Thus, baseline renal function data within 7 days preceding
surgery was available in all patients. During followup, the
time from ICD implantation to the ﬁrst appropriate ICD
shock was ascertained by reviewing device interrogation
and clinic records. Appropriate shock was deﬁned as a
shock delivered secondary to ventricular tachycardia or
ventricular ﬁbrillation as per treating Electrophysiologist’s
interpretation (shocks for supra ventricular arrhythmias and
thoseduetodevicemalfunctionwereexcluded).Thesurvival
status was ascertained from review of medical records and
veriﬁed from online Social Security Death Index database.
We used the baseline variables to estimate GFR using the
simpliﬁed Modiﬁcation of Diet in Renal Disease (sMDRD)
study prediction equation [11].
The sMDRD (mL/min per 1.73m2)i sc a l c u l a t e da s
follows:
(i) Male: 186.3 × (serum creatinine)−1.154 × (age)−0.203;
(ii) Black male: sMDRD × 1.212;
(iii) Female: sMDRD × 0.742;
(iv) Black female: sMDRD × 1.212 × 0.742.
Patients were stratiﬁed into 3 groups: normal renal
function or mild CKD, moderate CKD, and severe CKD.
Based on the National kidney Foundation classiﬁcation,
CKD stage 1 and 2 constituted group 1, CKD stage 3
constituted group 2, and CKD stages 4-5 constituted group
3[ 12]. The objective of this study was to determine the
eﬀect of moderate to severe CKD not requiring maintenance
dialysis on the time to ﬁrst appropriate ICD shock and all-
cause mortality. The study was approved by the Institutional
Review Board at Creighton University.
3.StatisticalAnalysis
The baseline characteristics of the groups were compared
using student t-test for continuous variables and the χ2
statistic for categorical variables. Continuous variables were
reported as mean with standard deviation and categorical
variables were reported as percentage. Survival analysis
for time to ﬁrst ICD shock was analyzed using Kaplan-
Meiermethod.UnivariateandmultivariateCoxproportional
hazard models were ﬁtted to derive unadjusted and adjusted
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Figure 1: Kaplan-Meier curves for time to ﬁrst appropriate ICD
shock based onGFR. The “+” signin the graphindicates censoring.
hazards for time to ﬁrst appropriate shock for variables
of interest. Predictors of mortality were assessed using
Generalized LinearModels(GLMs) with log-link function to
account for high risk of death in the study sample; risk ratios
(RRs) and 95% conﬁdence intervals (CI) were calculated.
All statistical analyses were performed using SAS 9.1 (SAS
Institute Inc, Cary, NC).
4.Results
4.1. Baseline Characteristics. Five hundred and nine consec-
utive patients with a mean followup of 3.0 years (Standard
Deviation [SD] 1.3 years) were included in the study.
Followup data was not available in 27 patients. Table 1
shows the characteristics of patients with ICD stratiﬁed by
GFR. Patients with lower GFR were older and more often
had ischemic heart disease as the underlying etiology. In
addition, they had a worse functional status (NYHA class
≥ 3) and a tendency towards lower hemoglobin. Medication
use including beta-blockers, angiotensin converting enzyme
(ace) inhibitors and antiarrhythmics was similar between the
2 groups except for loop diuretics which were used more
often in the patients with lower GFR.
4.2. Time to First Appropriate Shock. One hundred seventy
seven patients (35%) received appropriate shock during a
mean followup of 3 years. Kaplan Meier curves showing
shock free survival for the 3 GFR groups is represented in
Figure 1. Patients with moderate CKD had similar median
shock-free survival time as patients with mild or no CKD.
However, signiﬁcantly shorter median shock-free survival
time was noted in patients with severe CKD (GFR <
30mL/min) compared to those with GFR ≥ 60mL/min (2.8
versus 4.2yrs). The hazard ratios (HR) from Cox propor-
tional hazard models for time to ﬁrst appropriate shock by
CKD stages are shown in Table 2.I nt h em u l t i v a r i a t eC o x
proportionate hazard model, LVEF < 30% and admission
for heart failure were also independently associated with
shorter time to shock. On the other hand, ICD implantationCardiology Research and Practice 3
Table 1: Baseline characteristics of the study population.
GFR ≥ 60 GFR 30–59 GFR < 30 P-value
(n = 289) (n = 188) (n = 32)
Age (years) 68 69 73 .04
Male Gender (%) 92 88 83 .10
DM 32 36 40 .08
Hypertension 71 78 82 .9
NYHA class ≥ 3 (%) 51 63 71 .04
QRS > 120msec (%) 30 49 54 .40
Ejection Fraction (mean) 32 32 28 .60
Ischemic heart disease 77 83 89 .04
BUN (mean) 20 34 48 <.03
Creatinine (mean) 1.0 1.4 1.8 <.01
Hemoglobin (mean) 14.0 13 12.6 .06
Indication:Primary Prevention (%) 72 76 84 .08
β blocker (%) 74 78 78 .97
ACEi (%) 63 58 54 .28
ARB (%) 14 22 21 .28
Aldosterone inhibitor (%) 6 8 9 .39
Digoxin (%) 52 50 51 .85
Loop diuretic (%) 48 64 68 .03
Statin (%) 69 64 60 .29
Anti-arrhythmic (%) 19 28 32 .44
DM: diabetes mellitus; BUN: blood urea Nitrogen; ACEi: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blockers; NYHA: New York
heart association; Statin: hydroxyl-methyl-glutaryl CoA inhibitors.
Table 2: Hazard ratios with 95% conﬁdence intervals for time to
ﬁrst appropriate shock based on GFR.
Unadjusted Adjusted∗
GFR (mL/min/1.73m2)
≥60 ref ref
30–59 (moderate CKD) 1.15 (0.84–1.58) 1.15 (0.83–1.58)
<30 (severe CKD) 1.92 (1.09–3.38) 2.42 (1.35–4.34)
∗Adjusted for age (≥75 or <75 years), sex, indication for ICD implantation
(primary/secondary), NYHA class, heart failure admission, antiarrhyth-
mic/betablockeruse, and LVEF (<30%, ≥30%).
for primary prevention was associated with longer time to
shock. Age, NYHA functional class, beta-blockers, and
antiarrhythmic drug use were not independently associated
with time to ﬁrst appropriate shock. Though information on
antitachycardia pacing (ATP) was recorded wherever avail-
able, the data pertaining to appropriate ATP was missing in
many patients. Furthermore, ICD programming pertaining
to number of zones (VT, VF) and ATP programming was
extremely variable during the study period. Hence, we did
not analyze time to appropriate ATP in this study.
4.3. Mortality. The risk of death in ICD patients strat-
iﬁed based on renal function is shown in Table 3.
Moderate CKD (GFR 30–59mL/min) had approximately
twofold increased risk of all-cause mortality compared
with mild or no CKD (GFR > 60mL/min). Severe
CKD (GFR < 30mL/min) had about ﬁvefold higher risk
of all-cause mortality. Kaplan Meier curves for survival
based on GFR are shown in Figure 2.I nt h em u l t i -
ple GLM models, LVEF < 30%, increased age, worse
NYHA class, no betablocker, use of aldosterone inhibitor
or digoxin and admission for heart failure were pre-
dictive of increased mortality. The relationship between
renal function and mortality remained unchanged when
serum creatinine was used in place of derived GFR
(Table 4). The risk of death increased progressively from 1st
to 4th quartile of serum creatinine (P for trend < .01).
5.Discussion
The principal ﬁnding of our study is that even moderate
degree of renal impairment is associated with increased
all-cause mortality in patients with ICD. Moreover, there
was a graded response with lower GFR conferring a pro-
portionately higher risk: GFR < 30mL/min had ﬁvefold
higher risk of all-cause mortality and GFR 30–59mL/min
had twofold higher risk of all-cause mortality. Additionally,
we demonstrated that CKD is associated with increased risk
for appropriate shock. However, with respect to ICD shocks,
only patients with GFR < 30mL/min had a signiﬁcantly
shorter implantation to ICD shock time. Though patients
with moderate CKD (GFR 30–59mL/min) had a trend
towards earlier shock, this did not reach statistical signiﬁ-
c a n c e .T h eﬁ n d i n g so fo u rs t u d ya r ei nl i n ew i t hp r e v i o u s
studies on the impact of CKD in patients with ICD [6–10].4 Cardiology Research and Practice
Table 3: Risk ratios and 95% conﬁdence intervals for all-cause mortality based on GFR.
GFR (mL/min/1.73m2) n¶ Death (%) Unadjusted Adjusted∗
≥60 278 11.9 ref ref
30–59 172 22.5 1.89 (1.24–2.90) 1.81 (1.18–2.78)
<30 32 57.1 4.81 (3.13–7.40) 4.63 (3.02–7.09)
∗Adjusted for age (≥75 or <75 years), sex, indication for ICD implantation (primary/secondary), NYHA class, antiarrhythmics, ace inhibitor, digoxin,
aldosterone blocker, and betablocker use and LVEF (<30%, ≥30%).
¶Followup data not available in 27 patients.
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Figure 2: Kaplan-Meiercurves forsurvival based on GFR. CatGFR:
0i m p l i e sG F R≥ 60; catGFR: 1 implies GFR 30–59; catGFR: 2
implies GFR < 30mL/min.
In contrast to prior studies, we excluded patients with end-
stage renal failure on dialysis in our study.
The high rate of arrhythmias in patients with CKD
has been attributed to several pathophysiologic mecha-
nisms including diastolic dysfunction, cardiac interstitial
ﬁbrosis, autonomic dysfunction, and adverse pharmacologic
interactions [13–16]. Potential reasons for high mortality
in CKD patients despite ICD implantation could be the
limitedeﬃcacyofICDinpreventingarrhythmic deathdueto
inappropriately high deﬁbrillation thresholds (DFT) or non-
SCD mechanisms for mortality [17–19]. Prior reports have
shown that DFT increases as a function of renal insuﬃciency
[7]. Alternatively, mortality from competing risk factors
could minimize the beneﬁts of ICD. The most commonly
reported underlying cause of death in patients with ICD
and CKD is progressive heart failure [10]. In the study by
Eckart et al., hospital admission for heart failure was three
timesmore commoninICDpatientswithCKDcompared to
those withoutrenal insuﬃciency[17].Infection and vascular
events are other common reasons for death in patients with
advanced renal failure, and could explain why the survival
beneﬁts of ICD are attenuated in this population [18, 19]. In
ourstudyadvancedage,poorNYHAclass,lowerLVEF,useof
digoxin and aldosterone inhibitors were other predictors of
all-cause mortality. Beta-blocker had a signiﬁcant protective
eﬀect on all-cause mortality and statins (hydroxy-methyl-
glutaryl coenzyme-A inhibitors) showed a trend towards
decreased mortality. In contrast to prior reports, beta-
blockers only demonstrated a trend towards decreasing ICD
discharge that did not reach statistical signiﬁcance in our
study [20]. Aldosterone inhibitors have proven beneﬁts in
patients with heart failure and low LVEF [21]; however,
thesestudiesexcludedpatientswithmoderatetosevereCKD.
The adverse mortality eﬀects of digoxin and aldosterone
inhibitors may be dueto combination of poor baseline status
(reﬂective of more advanced heart disease) or increased
adverse eﬀects of these drugs in CKD populations (like
hyperkalemia).
In a retrospective analysis of the patients enrolled in the
Multicenter Automatic Deﬁbrillator Implantation Trial-II,
ICD implantation signiﬁcantly reduced mortality in patients
with estimated GFR > 35ml/min/1.73m2 (risk reduction
for all-cause mortality 32%, P = .01), but had no beneﬁt
in patients with a GFR < 35ml/min/1.73m2 (all-cause
mortality hazard ratio 1.09, P = .84) [22]. On the other
hand, Herzog et al. demonstrated survival beneﬁt with
ICD implantation in dialysis-dependant patients following
aborted cardiac arrest [23]. Notably, the limited eﬃcacy of
therapy in patients with renal dysfunction is not unique
to ICD. There is evidence suggesting that the beneﬁts of
other life saving interventions like coronary angioplasty
and coronary artery bypass grafting are similarly blunted
in patients with CKD compared to those without [3, 24].
Thus, in patients who are candidates for ICD, the presence
of renal impairment creates a unique and complex set of
issues. The incidence of cardiovascular events, ventricular
arrhythmias, and sudden death is high indicating high
likelihood of beneﬁt. On the other hand, the beneﬁcial
eﬀects of ICD appear to be less than expected or in fact
questionable. This is likely to be multifactorial, related to the
diminished eﬃcacy of ICDs in these patients, higher rates
of device-related complicationslike infection and competing
risks like heart failure, and vascular disease which increase
nonarrhythmic mortality [17–19, 24–27]. In our study, 33
patients (7%) developed device-related complications (early
and late) which included pocket infection, hematoma need-
ing exploration, pneumothorax, endocarditis, and cardiac
perforation by ICD lead. There was no signiﬁcant diﬀerence
among the diﬀerent GFR groups.
Additionally, there is evidence to suggest that ICDs like
all other life saving medical and surgical interventions are
grossly underutilized in CKD populations; less than 10% of
renal failure patients surviving a sudden cardiac arrest getCardiology Research and Practice 5
Table 4: Risk ratios and 95% conﬁdence intervals for all-cause mortality based on serum creatinine.
Serum creatinine (mg/dL) n Death (%) Unadjusted Adjusted∗
1st quartile (<1.0) 108 7.41 ref ref
2nd quartile (1.0–) 128 13.28 1.79 (0.81–3.99) 1.77 (0.80–3.94)
3rd quartile (1.2–) 110 20.00 2.70 (1.26–5.80) 2.72 (1.28–5.82)
4th quartile (1.4–) 136 32.35 4.37 (2.15–8.88) 3.73 (1.84–7.58)
∗Adjusted for age (≥75 or <75 years), sex, indication for ICD implantation (primary, secondary), NYHA class, antiarrhythmics, ace inhibitor, digoxin,
aldosterone blocker, and betablocker use and LVEF (<30%, ≥30%).
an ICD [3, 23]. While “therapeutic nihilism” is one poten-
tial contributing factor, the lack of strong evidence base
supporting the beneﬁt of these interventions is another
major limitation. Given the controversies about potential
overestimation of ICD beneﬁts (at least in the primary pre-
vention setting) and the concerns about cost-eﬀectiveness, it
is imperative for researchers to evaluate the beneﬁts of ICDs
in CKD populations in well-designed large scale prospective
randomized trials [27]. Furthermore, risk prediction models
that diﬀerentiate between CKD patients who will and will
not beneﬁt from ICD implantation need to be developed
and prospectively validated to ensure optimal selection of
candidates. In a provocative paper, Amin et al. determined
that the beneﬁt of ICD in patients with renal insuﬃciency is
limited to patients with age <80 for stage 3, age <75 for stage
4, and age <65 for stage 5 using a complex prediction model
[28].
6.Strengthsand Limitations
Our study is a single center, retrospective observational
study. As is the case with all observational studies, thequality
of data is limited by accuracy of data collection and storage.
We made an exhaustive eﬀort to collect all data elements and
multiplerecordsourceswithlinkingtechniquesbeingusedin
order to minimize errors and deﬁciencies. We were however,
unableto ascertain the cause of death.In addition, creatinine
clearance was estimated based on a one time measurement;
hence,thereis a potentialfor misclassiﬁcation bias.Similarly,
residual confounding cannot be excluded despite statistical
adjustments for known confounders due to the retrospective
nature of the study. An additional limitation is that the study
population was predominantly Caucasian and males; hence
it was not a representative sample. However, this is reﬂective
of real word ICD implantation practices as it is well known
that female sex and African American race are associated
with lower rates of ICD implantation [29, 30]. Furthermore,
majority of our patients had ischemic heart disease as the
underlying substrate. An additional limitation was the use of
time to shock rather than time to appropriate ICD therapy
(shock and ATP). Thoughthe latterisa more comprehensive
end point, ICD shock has more clinical relevance. Moreover,
ATPprogramming isextremely variableanddeterminingif it
is appropriate versus inappropriate is more prone for error.
The relatively large number of patients studied is a major
strength of our study. Only a couple of studies of similar size
have assessed the association between CKD and mortality in
ICD populations [6, 10, 17, 31]. Unlike other studies, our
study excluded dialysis-dependant patients who have a very
high mortality. Despite this, we could demonstrate a strong
association between moderate-severe CKD and mortality.
In addition, our study evaluated the time to appropriate
shock which has not previously been studied in patientswith
moderate-severe CKD.
7.Conclusions
Our results support ﬁndings from previous studies showing
higher mortality in ICD patients with CKD [6–10, 17, 31].
This is true even with moderate degree of renal dysfunction
and nondialysis-dependant patients. In addition, our study
demonstrates that patients with severe CKD have lower
shock-free survival. There is an urgent need to develop
and test risk scoring systems incorporating GFR along with
other clinical factors that can reliably identify CKD patients
who will beneﬁt from ICD implantation. The need for
large, randomized, and prospective clinical trials assessing
the impact of ICD on survival, quality of life, and cost-
eﬀectiveness in patients with CKD cannot be overstated.
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